 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/364373
World Gene Therapy Market
|
Description: |
Combination Trials in Gene Therapy Market to Improve Clinical Efficiency
Recent failures of clinical trials in gene therapy have caused the termination of several research projects and the retraction of many participants from the market. Only one gene therapy product, Gendicine, has reached the market in China, and its launch has been weighed down with debates about regulatory concerns over its clinical safety and efficacy. However, gene therapy still holds promise as a potential one-stop treatment for life threatening diseases. An increasingly popular method of improving clinical efficiency is to combine gene therapy trials with conventional therapeutics. These combination trials sometimes involve collaboration outside the gene therapy market with companies having established products or expertise in healthcare.
This Frost & Sullivan insight examines the current status of the world gene therapy market with a focus on its benefits and drawbacks and upcoming trends. It also provides market drivers and restraints as well as strategic analyses and recommendations to overcome industry challenges. This research enables companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investment.
High Prevalence of Untreatable Diseases Drives Demand for New Treatments
The gene therapy market has seen both devastating clinical failures and incredible breakthroughs for the treatment of severe diseases. The launch of Gendicine finally signifies a huge boost for gene therapy. The risks historically associated with gene therapy are now lessening, predominantly through scientific advances in gene delivery by industry participants.
Numerous products are in the clinical pipeline with regulatory approval anticipated within the next three years, says the analyst of this research. The market faces major challenges in patient recruitment and in the improvement of clinical success, but if these are overcome, the results will herald a new era of medicine.
First Gene Therapy Products Approach the Market
The Chinese State Food and Drug Administration (FDA) approved Gendicine for the treatment of head and neck cancer, for sale in China in January 2004. Following this first authorization, there have been a substantial number of products in the clinical development pipeline poised to reach the European and the United States markets. Many of these products have achieved regulatory fast track and ‘orphan drug’ status, as they represent areas of unmet medical need.
Revenue generated from sales of these products can potentially reach $5.73 billion by 2011, notes the analyst. The gene therapy market is therefore poised to have a significant impact on the healthcare industry, provided that current market and technical challenges are overcome.
|
|
Contents: |
1. Executive Summary
- 1. Executive Summary
- - 1. Executive Summary
2. Glossary
- 1. Glossary
- - 1. Glossary
3. Introduction
- 1. Gene Therapy-An Overview
- - 1. Market Definition
- - 2. Technologies Used in Gene Therapy
4. Market Overview
- 1. Market Challenges
- - 1. Challenges for the Gene Therapy Market
- - - a. Lack of Clinical Success
- - - b. High Levels of Surveillance and Compliance Expectations from Regulatory Agencies
- - - c. Negative Perception and Acceptance of Gene Therapy
- - - d. Technical and Safety Issues over Gene Delivery Specificity
- - - e. Lack of Standardisation of Clinical Procedures and Manufacturing Methodologies
- - - f. High Anticipated Cost of Gene Therapy Products
- 2. Clinical Research Trends in Gene Therapy
- - 1. Research Trends
- - 2. Clinical Pipeline Analysis
- 3. Regulatory Affairs
- - 1. Regulatory Affairs in the United States
- - 2. Regulatory Affairs in Europe
5. Market Analysis
- 1. Research Methodology
- - 1. Methodology and Assumptions
- 2. Market Drivers and Restraints
- - 1. Market Drivers
- - - a. Demand for Treatments for Areas of Unmet Medical Need
- - - b. Licensing of Key Gene Delivery Patents Generates Market Revenue
- - - c. New Technologies Improve Transgene Expression
- - - d. Human Genome Project Provides New Leads
- - 2. Market Restraints
- - - a. Clinical Failures and Patient Fatalities
- - - b. Retraction of Key Industry Participants and Pharmaceutical Giants
- - - c. Patient Recruitment Issues in Clinical Trials
- - - d. High Cost of Finished Products
- 3. Market Analysis
- - 1. Market Engineering Measurements
- - 2. Revenue Forecasts
6. Competitive Analysis
- 1. Competitive Structure
- - 1. Competitive Highlights
- 2. Competitive Analysis
- - 1. Competitors in the Gene Therapy Market-Oncology
- - 2. Competitors in the Gene Therapy Market-Cardiovascular
- - 3. Competitors in the Gene Therapy Market-Monogenic
- - 4. Competitors in the Gene Therapy Market-Enabling Technologies and Generalist Providers
7. Strategic Analysis and Recommendations
- 1. Market Engineering Strategy
- - 1. Strategic Analysis
- - 2. Strategic Priorities
8. Frost & Sullivan Awards
- 1. Frost & Sullivan Award Candidates
- - 1. Introduction to Frost & Sullivan Awards
- - 2. Technology Leadership Award
- - 3. Entrepreneurial Company Award
- - 4. Growth Strategy Leadership Award
9. Decision Support Databases
- 1. Pharmaceutical and Biotechnology Market Metrics
- - 1. Number of Biotechnology Companies
- - 2. Biotechnology Private Investment
- - 3. Government Investment in Biotechnology
- - 4. Total Healthcare Expenditure
- 2. Disease Prevalence
- - 1. Prevalence of Bladder Cancer
- - 2. Prevalence of Breast Cancer
- - 3. Prevalence of Colon Rectum Cancer
- - 4. Prevalence of Liver Cancer
- - 5. Prevalence of Lung Cancer
- - 6. Prevalence of Prostrate Cancer
- - 7. Prevalence of Stomach Cancer
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/364373
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 26/11/2009 12:27:48 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
World Gene Therapy Market
|
|
Web Address: |
http://www.researchandmarkets.com/reports/364373
|
|
Office Code: |
|
OC8HJNMPMSTQQ
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Site License
|
|
€4,500.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€5,507.00
|
|
Electronic and Hard Copy (PDF)
- Enterprisewide
|
|
€5,843.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic and Hard Copy (PDF)
- Site License
|
|
€4,836.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 26/11/2009 12:27:48
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
